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Abstract
 
We studied the function of antitumor T and natural killer T (NKT) cells from the blood and
tumor bed in 23 patients with premalignant gammopathy, nonprogressive myeloma, or pro-
gressive multiple myeloma. We show that antitumor killer T cells can be detected in patients
with both progressive or nonprogressive myeloma. V
 
 
 
24
 
 
 
V
 
 
 
11
 
 
 
 invariant NKT cells are de-
tectable in the blood and tumor bed of all cohorts. However, freshly isolated NKT cells from
both the blood and tumor bed of patients with progressive disease, but not nonprogressive
myeloma or premalignant gammopathy, have a marked deficiency of ligand-dependent inter-
feron-
 
 
 
 production. This functional defect can be overcome in vitro using dendritic cells
pulsed with the NKT ligand, 
 
 
 
-galactosylceramide (
 
 
 
-GalCer). Fresh myeloma cells express
CD1d, and can be efficiently killed by autologous NKT cells. We hypothesize that presenta-
tion of tumor derived glycolipids by myeloma cells leads to NKT dysfunction in vivo. These
data demonstrate that clinical progression in patients with monoclonal gammopathies is associ-
ated with an acquired but potentially reversible defect in NKT cell function and support the
possibility that these innate lymphocytes play a role in controlling the malignant growth of this
incurable B cell tumor in patients.
Key words: multiple myeloma • NKT cells • dendritic cells • interferon-
 
 
 
 • immunotherapy
 
Introduction
 
Clonal expansion of a transformed cell is a prerequisite for
the development of cancer, but such expansions can remain
stable for prolonged periods without the development of
overt clinical malignancy in patients (1–3). Monoclonal
gammopathies are characterized by the proliferation of a
transformed clone of plasma cells (3, 4). However the
clinical outcome of this clonal expansion can vary greatly.
Patients with monoclonal gammopathies of undetermined
significance (MGUS)
 
*
 
 often remain stable for several years,
and are thought to have a clinically “premalignant” state.
Even some patients with greater clonal burden meeting di-
agnostic criteria for myeloma can remain stable for pro-
longed periods (“nonprogressive myeloma”; NPM), while
those with progressive myeloma (PM) have a limited sur-
vival, even after high dose chemotherapy (4). Clinical
management of these patients is therefore a challenge, be-
cause current therapies are not curative and tumor pro-
gression in patients with MGUS or myeloma is difficult to
predict. This is particularly puzzling because in recent stud-
ies, nearly all of the cytogenetic changes initially described
in myeloma tumor cells have now also been observed in
plasma cells from MGUS (5, 6). Furthermore, recent studies
of gene expression profiles have also failed to demonstrate
clear differences between purified plasma cells in MGUS or
myeloma (7). One possibility that we address here, is that
the host response plays a key role in controlling the “malig-
nant transformation” of this cancer.
In mice, components of both the adaptive (cytolytic
killer and helper T lymphocytes) and the innate immune
system (natural killer [NK], and NKT cells), as well as IFN-
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Abbreviations used in this paper:
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 galactosylceramide; DC,
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cance; NKT, natural killer T; NPM, nonprogressive myeloma; PM, pro-
gressive myeloma; SEA, staphylococcal enterotoxin A.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
1668
 
NKT Dysfunction in Myeloma
 
are important for the surveillance of spontaneous as well as
carcinogen induced tumors (8–10). In human cancer, mul-
tiple myeloma provides a valuable opportunity to study
these innate and adaptive defense mechanisms, because of
the ease of access to the tumor and immune cells in the tu-
mor bed, the bone marrow, without the need for enzy-
matic manipulations and in vitro culture. Recently we ob-
served that freshly isolated T cells from the tumor bed of
patients with progressive myeloma do not react detectably
to their autologous tumor (11). However, both cytolytic
and IFN-
 
 
 
 producing response to autologous myeloma
could be reliably generated following stimulation with tu-
mor-loaded dendritic cells (DCs), even though these pa-
tients had clinically progressive tumors (11).
Human natural killer T (NKT) cells are distinct lympho-
cytes, which often use a restricted T cell receptor (V
 
 
 
24-
V
 
 
 
11 in humans) that recognizes glycolipid ligands in the
context of a nonpolymorphic antigen presenting molecule,
CD1d (for reviews, see references 12–14). NKT cells can
be activated by a synthetic ligand, 
 
 
 
-galactosyl ceramide
(
 
 
 
-GalCer; reference 15), leading to rapid production of
several cytokines such as IL-4 and IFN-
 
 
 
. In mice, 
 
 
 
-Gal-
Cer stimulation of NKT cells regulates autoimmunity, as
well as resistance to infections, and tumors (16–21), and
preliminary evidence for such effects are evident with hu-
man cells (22, 23) (for reviews, see references 12–14). Defi-
ciencies in IFN-
 
  
 
production and the proliferative poten-
tial of NKT cells have recently been described in some
patients with advanced cancer (24, 25). However, it is diffi-
cult to interpret the significance of an alteration in immune
function, unless one understands its relationship to the de-
velopment or clinical outcome of a disease, and the benefit
of its functional restoration, particularly in the context of
autologous fresh tumor. Here we measure antitumor killer
T and NKT cell function in clinically distinct cohorts of
patients with monoclonal gammopathies.
 
Materials and Methods
 
Study Subjects.
 
Peripheral blood and bone marrow samples
were obtained from patients with monoclonal gammopathies fol-
lowing informed consent approved by the institutional review
board. Patients were classified as MGUS or myeloma, according
to standard diagnostic criteria (4). Myeloma patients were further
classified either as progressive if they experienced disease progres-
sion by standard criteria (4), or as nonprogressive, if they did not
experience disease progression or require therapy for at least 3 mo
after the blood draw. All patients with progressive disease were
studied before the initiation of any chemotherapy.
 
Isolation of Tumor and Immune Cells.
 
Mononuclear cells from
blood or bone marrow were obtained by density gradient centrif-
ugation using Ficoll Hypaque. DCs were generated from mono-
cytes by culture of adherent blood mononuclear cells in the pres-
ence of GM-CSF (Immunex) and IL-4 (R&D Systems) as
described (26). Nonadherent cells were used as a source of blood
T cells. Bone marrow mononuclear cells were separated into tu-
mor (CD138
 
 
 
ve) and nontumor (CD138-ve) fractions using
CD138 magnetic beads (Miltenyi Biotec). Tumor cells were cryo-
preserved in aliquots for use as sources of antigen, as well as tar-
 
gets. Non tumor cell fractions were also cryopreserved for use as
control targets, as well as a source of T cells from the marrow.
 
Generation of Antigen-loaded DCs.
 
Autologous tumor cells
were opsonized using anti-syndecan-1, 
 
 
 
-irradiated, and then fed
to immature DCs as described (26). DCs were then induced to
mature by overnight culture in the presence of a cytokine cock-
tail consisting of TNF-
 
 
 
 (10 ng/ml), IL-1
 
 
 
 (10 ng/ml), IL-6
(1,000 U/ml; all from R&D Systems), and PGE
 
2
 
 (1 
 
 
 
g/ml; Am-
ersham Biosciences). For stimulation of NKT cells, 
 
 
 
-GalCer
(100 ng/ml; kindly provided by Kirin Breweries, Gunma, Japan)
was loaded on DCs overnight on day 6–7 of culture, together
with the cytokine cocktail for maturation.
 
Stimulation of T/NKT Cell Responses in Culture.
 
To stimu-
late tumor specific T cells, tumor-loaded mature DCs (or un-
pulsed as the negative control) were cocultured with autologous
T cells (2 
 
 
 
 10
 
5
 
 cells/well) from either the marrow or blood at a
DC:T cell ratio of 1:10–30 in 200 
 
 
 
l of 5% pooled human serum
(11, 26). Cultures were supplemented with IL-2 (Chiron Corp.)
on days 4 and 7 (10 U/ml). In some experiments, IL-7 (R&D
Systems; 5 ng/ml) was added to cultures on day 7. After 12–16 d
in most experiments, T cells from several micro-cultures were
pooled and tumor-specific killer T cells were assayed by cytotox-
icity and ELISPOT assays, as described (11).
To expand NKT cells in culture, M
 
 
 
-depleted cells or PB-
MCs (10
 
5
 
/well) were cultured with autologous 
 
 
 
-GalCer loaded
DCs (or unpulsed DCs as a control) in the presence of recombi-
nant IL-2 (50 U/ml) for 1–3 wk, as described (27). IL-2 (50
U/ml) was supplemented weekly. 
 
 
 
-GalCer–dependent expan-
sion of NKT cells was monitored by quantifying V
 
 
 
24
 
 
 
V
 
 
 
11
 
 
 
cells by FACS
 
®
 
.
 
Single Cell ELISPOT Assay for Quantifying NKT and T Cells.
 
Freshly isolated PBMCs (5 
 
 
 
 10
 
5
 
/well) were incubated for 16 h
either with or without 
 
 
 
-GalCer (100 ng/ml) in 5% heat inacti-
vated human serum containing RPMI (complete medium or
CM) in ELISPOT plates precoated with anti–IFN-
 
 
 
 or IL-4 an-
tibodies, as described (27). In prior studies with healthy donors,
we have shown that 
 
 
 
-GalCer reactive IFN-
 
 
 
 producers in this
assay are depleted after the removal of V
 
 
 
24
 
 
 
 or V
 
 
 
11
 
 
 
 cells and
correlate only with the number of NKT, but not number of NK
or T cells, strongly suggesting that the reactivity in this ELISPOT
assay is a quantitative measure of NKT function (27). This is also
supported by the finding of Gumperz et al., who also did not find
cytokine production by nontetramer binders in response to over-
night 
 
 
 
-GalCer stimulation of fresh human PBMCs in vitro (28).
For detecting influenza virus–specific T cells, PBMCs were in-
fected with influenza virus (MOI 
 
  
 
2) before plating in the
ELISPOT assay, as described (29). PHA (10 
 
 
 
g/ml) and staphylo-
coccal enterotoxin A
 
 (
 
SEA; 50 ng/ml) were used as a positive con-
trol. The presence of tumor-reactive IFN-
 
 
 
–producing T cells in
both blood and marrow T cells was also quantified by ELISPOT
both directly ex vivo, and after in vitro stimulation (as described
above), with autologous tumor loaded DCs, as described (11, 26).
For some experiments, T cells expanded using 
 
 
 
-GalCer pulsed
DCs were separated into V
 
 
 
24 positive or negative fractions and
tested for recognition of unpulsed or 
 
 
 
-GalCer pulsed DCs using
an ELISPOT assay for IFN-
 
 
 
 or IL-4 production.
 
Flow Cytometric Analyses.
 
FITC-labeled murine IgG, PE-
labeled murine IgG2a, anti–human CD3, anti-CD8, anti-CD4,
anti-CD14, and anti-CD56 mAbs were purchased from Becton
Dickinson, and FITC-labeled anti-V
 
 
 
24 and PE-labeled anti-
V
 
 
 
11 from Beckman Coulter. In samples with low frequencies
of NKT cells, analyses were repeated with acquisition of at least
1–3 
 
 
 
 10
 
5
 
 lymphocyte gated events, to confirm the frequency ofT
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NKT cells. To test the functional properties of freshly isolated
uncultured NKT cells, PBMCs were cultured in 96-well plates
with 
 
 
 
-GalCer (100 ng/ml) and purified anti-CD28 (3 
 
 
 
g/ml;
BD Biosciences), or anti-CD28 alone as a control, in the pres-
ence of 0.7 
 
 
 
g/ml of Golgistop (from Cytofix/CytoPerm Plus
Kit from BD Biosciences). Preliminary studies had shown the
need for anti-CD28 for enhancing the sensitivity of reliable de-
tection of 
 
 
 
-GalCer reactive cytokine producers in this system, as
shown previously (30). After overnight (12–16 h) culture at
37
 
 
 
C, cells were washed and stained for surface markers, and then
washed two more times in staining buffer. Cells were then fixed
and permeabilized in 100 
 
 
 
l cytofix/cytoperm solution using
manufacturer’s directions, and stained for intracellular cytokines
(IFN-
 
 
 
 and IL-4). Reagents used for staining were anti-V
 
 
 
24-
FITC, (Immunotech), anti-CD3-Cychrome, anti-CD4 APC,
and anti–IFN-
 
 
 
-PE or anti–IL-4-PE (BD Biosciences). Samples
were analyzed on FACSort™ or FACSCalibur™ (Becton Dick-
inson) instrument using CELLQuest™ software. Lymphocyte
events collected were typically 1–3 
 
 
 
 10
 
5
 
 events per sample.
Functional aspects of NKT cells expanded using 
 
 
 
-GalCer pulsed
DCs were also evaluated by monitoring intracellular cytokine
(IFN-
 
 
 
, IL-4) expression by flow cytometry after 6 h stimulation
with PMA (50 ng/ml) and ionomycin (1 
 
 
 
M).
 
Cytolysis Assays.
 
The presence of tumor specific killer T cells
in bulk T cell cultures after in vitro stimulation with tumor cell–
loaded DCs was evaluated using standard 5 h 
 
51
 
Cr release assays,
with autologous tumor cells (CD138
 
 
 
) as targets, with autolo-
gous nontumor fractions from the tumor bed of the same patient
as controls, as described (11, 26). To test cytolysis by NKT cells,
bulk cultures expanded using 
 
 
 
-GalCer pulsed DCs were sepa-
rated into V
 
 
 
24 positive and negative fractions using magnetic
beads and tested in cytolysis assays. Purity of fractions was moni-
tored by FACS
 
®
 
 and was 
 
 
 
80%. For some experiments, target
cells were tested with or without pulsing with 100 ng/ml 
 
 
 
-Gal-
Cer, or pretreated with anti-human CD1d antibody (5 
 
 
 
g/ml,
clone 42; BD Biosciences) or isotype control.
 
Statistical Analysis.
 
Data for immune reactivity between two
groups was compared using Student’s 
 
t
 
 test, and Mann Whitney
test. Kruskall Wallis test was used when more than two groups
were compared. Significance was set at P 
 
  
 
0.05.
 
Results
 
Comparable Antitumor Killer T Cell Function in Progressive
and Nonprogressive Myeloma.
 
To assess general immune
competence, we first quantified influenza virus–specific T
cells, as well as response to superantigen SEA in fresh lym-
phocytes from 4 groups of individuals: patients with
MGUS, nonprogressive myeloma (defined as asymptom-
atic and stable disease for 
 
 
 
3 mo), progressive myeloma,
and healthy controls. Immune reactivity to influenza (P 
 
 
 
0.3) and SEA was comparable in all 4 cohorts indicating
general immune competence (Fig. 1 A). We next hypoth-
esized that the state of clinical stability in patients with
nonprogressive myeloma may be due to enhanced activa-
tion and expansion of antitumor T cells with rapid effector
function. To test this, we measured the immune reactivity
of T cells from 3 consecutive patients with nonprogressive
myeloma, and compared it to the data from 8 patients with
progressive tumors. Freshly isolated circulating T cells
from patients with nonprogressive tumors did not react
detectably with autologous tumor for IFN-
 
  
 
production
(Fig. 1 B). Similar findings were observed when T cells
from the tumor bed of these patients were tested (unpub-
lished data). However, after 14–16 d of stimulation using
autologous tumor loaded DCs, reactivity against autolo-
gous tumor (but not against nontumor cells in the tumor
bed) was generated from all three patients. Contrary to our
expectations, this reactivity was quantitatively similar to
the reactivity of T cells from patients with clinically pro-
gressive disease, which develop tumor reactive killer cells
as reported (11) when cultured under identical conditions
(P 
 
  
 
0.76, Fig. 1 B). Thus, antitumor effector T cell func-
tion, as measured in our assays with both fresh and cul-
tured T cells for reactivity against autologous tumor, was
similar between patients with clinically progressive or
nonprogressive myeloma.
 
Detection of NKT Cells in Patients with Monoclonal Gammo-
pathies.
 
Given the difficulty in identifying clear distinc-
tions in antitumor CD8
 
 
 
 T cells in patients with progres-
Figure 1. (A) Influenza and SEA reactive T cell response in monoclo-
nal gammopathies. ELISPOT assay quantifying the presence of influenza
and SEA reactive T cells in patients with m MGUS (n   6), NPM (n  
3), PM (n   8), or healthy donors (HD, n   5). Each dot represents an
individual patient. (B) Antitumor T cell function in progressive or non-
progressive myeloma. ELISPOT assay testing IFN-  production in re-
sponse to autologous tumor (CD138 ) or nontumor (CD138-ve) cells
from bone marrow, by blood T cells tested either fresh immediately after
isolation, or after in vitro expansion using autologous tumor loaded DCs.
Each dot represents an individual patient.T
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sive or nonprogressive myeloma, we focused on the natural
killer T (NKT) cells. These bear a restricted T cell receptor
(V 24-V 11) and can be activated by a synthetic ligand,
 -galactosyl ceramide ( -GalCer; references 12–14).
V 24 V 11  NKT cells could be detected by flow cy-
tometry in PBMCs from patients with progressive (n   7)
or nonprogressive myeloma (n   4), MGUS (n   10), or
healthy controls (n   13) (Fig. 2 A). The frequency of
NKT cells in progressive myeloma (mean   SD; 0.045  
0.04%) overlapped with that in patients with nonprogres-
sive disease (0.064   0.05%), MGUS (0.073   0.07%), or
healthy donors (0.068   0.06%; P   0.8; Kruskall Wallis).
Similarly, the frequency of T (CD3 ve) and NK cells
(CD3-ve, CD56 ve) were also comparable between these
cohorts (P   0.8 for comparison of NK cells, and P   0.7
for comparison of T cells; Fig. 2 B).
Decreased NKT Effector Function in Progressive Myeloma.
We have recently shown that the presence of functional
human NKT cells in fresh blood can be readily quantified
using an ELISPOT assay measuring cytokine production in
response to NKT ligand,  -GalCer (27).  -GalCer reactive
IFN-  producting NKT cells could be readily detected in
fresh PBMCs from healthy donors, patients with MGUS or
nonprogressive myeloma (Fig. 3 A). In contrast, there was a
marked decline in  -GalCer reactive IFN-  production in
patients with progressive myeloma (Fig. 3 A). Thus the
mean ( SD)  -GalCer reactive IFN-  producers were sig-
nificantly lower in fresh blood of patients with progressive
myeloma (1.8   2.4 per 106 PBMCs) than in patients with
nonprogressive disease (60.5   48.8), MGUS (78.5  
37.7), or healthy controls (65   39.6; P   0.001). This loss
of IFN-  production by NKT cells in progressive myeloma
was not associated with detectable  -GalCer–reactive IL-4
production (Fig. 3 A). PHA induced T cell activation
served as positive control for IL-4 production in these as-
says (unpublished data). IFN-  producers detected in this
assay were NKT dependent because they could be re-
moved by the depletion of V 24  or V 11  fraction, be-
fore use in the assay (Fig. 3 B). When patients with pro-
gressive myeloma (who lacked detectable functional NKT
cells) were excluded, detection of  -GalCer–reactive IFN- 
producers in fresh blood in the ELISPOT assay correlated
with the number of NKT (r2   0.8), but not NK cells or T
cells by flow cytometry (unpublished data), similar to prior
studies in healthy donors (27).
The loss of  -GalCer–reactive IFN-  producers in my-
eloma patients was not due to the loss of resident APC
function in myeloma PBMCs, as influenza infection of
these PBMCs led to efficient activation of influenza specific
T cells (Fig. 1 A). We have recently shown that the nature
of the APC expressing NKT ligand has a significant impact
on activation of resting human NKT cells (27). Thus ma-
ture DCs were superior to monocytes for activation of
NKT cells and improve the detection of NKT function in
fresh blood (27). The use of  -GalCer–pulsed mature DCs
did lead to improved detection of functioning NKT cells in
the PBMCs from blood of patients with nonprogressive
myeloma, but again, no IFN-  producers could be de-
tected in the blood of patients with clinically progressive
disease, when tested immediately after venapuncture (Fig.
3 C, compare open with closed bars).
Next, we examined the numbers and function of NKT
cells in the tumor bed of myeloma patients. The numbers
of V 24 V 11  NKT cells detected by flow cytometry in
the bone marrow mononuclear cells were comparable to
those in the fresh blood, in patients with either progres-
sive or nonprogressive myeloma (unpublished data). Again
however, patients with progressive disease had fewer
 -GalCer–reactive IFN-  producers in their tumor bed (Fig.
3 D). Although human bone marrow has been shown to
contain Th2-like, noninvariant TCR, CD1d reactive cells
(31), no  -GalCer–reactive IL-4 producers were detected
among marrow T cells (Fig. 3 D). To directly detect cyto-
kine production in response to  -GalCer by uncultured
NKT cells, we also examined intracellular cytokine pro-
duction by flow cytometry (30). A fraction of V 24  cells
secreting IFN-  in response to  -GalCer stimulation could
be readily detected in patients with MGUS or nonprogres-
sive myeloma, similar to prior studies (Fig. 3 E; references
28 and 30). In contrast, no ligand reactive IFN-  produc-
tion was detected in NKT cells from patients with non-
progressive myeloma, confirming our studies with the
Figure 2. (A and B) Quantitation of NKT (V 24  V 11 ) (A), NK
(CD3 CD56 ), and T cells (B) by flow cytometry in PBMCs of healthy
donors (HD; n   13), or patients with MGUS (n   10), NPM (n   4),
or PM (n   7).T
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ELISPOT assay (Fig. 3 E). The proportion of invariant
TCR (V 24 V 11 ) positive T cells among V 24  cells
in progressive myeloma was comparable to all other study
cohorts (unpublished data).  -GalCer reactive cytokine
production in these assays was restricted to the
CD3 V 24  T cells, and not the V 24  T cells, or CD3
negative population (Fig. 3 E), which is similar to prior
studies showing that cytokine production after  -GalCer
stimulation was detected only in a fraction of CD1d tet-
ramer binding NKT cells (28). These data support our con-
clusion that the  -GalCer–reactive IFN-  producers in the
ELISPOT assay are predominantly NKT cells. Together,
these data suggest that freshly isolated NKT cells from pa-
tients with progressive myeloma have a defect in IFN- 
production in response to ligand stimulation.
DC-mediated Expansion of Functional NKT Cells in Patients
with Progressive Myeloma. We and others have recently
shown that mature DCs loaded with  -GalCer are efficient
Figure 3. Function of fresh uncultured NKT cells in monoclonal
gammopathies. (A) Loss of  -GalCer–reactive IFN-  production in fresh
NKT cells in progressive myeloma. ELISPOT assay quantifying the pres-
ence of  -GalCer reactive IFN- /IL-4 producers in fresh PBMCs from
healthy donors (HD; n   13), or patients with MGUS (n   10), NPM
(n   4), or PM (n   9). (B) Effect of depletion of various cell populations
on  -GalCer–reactive IFN-  production in fresh PBMCs. PBMCs were
depleted before the  -GalCer stimulated ELISPOT assay using anti-
V 24 , V 11 , CD3 , CD8 , or isotype control antibody, followed by
magnetic bead depletion. Data shown are percentage of reactivity in whole PBMCs. (C) Fresh NKT cells from progressive myeloma do not react to
ligand bearing DCs. ELISPOT assay quantifying the presence of  -GalCer–reactive IFN- /IL-4 producers in fresh PBMCs from a representative patient
with progressive or nonprogressive myeloma, using PBMCs alone or autologous mature DCs (added to PBMCs at PBMC:DC ratio of 20:1) as APCs
during the 16 h ELISPOT assay. Data represent two patients from each cohort. (D) Loss of effector NKT function in the tumor bed of patients with PM,
but not those with NPM myeloma. ELISPOT assays quantifying the presence of  -GalCer–reactive IFN- /IL-4 producers in fresh mononuclear from
blood or bone marrow (tumor bed) of two patients with progressive or nonprogressive myeloma. (E) Detection of ligand reactive cytokine production by
uncultured NKT cells of patients with progressive or nonprogressive myeloma using flow cytometry. PBMCs were stimulated with  -GalCer   anti-
CD28, or anti-CD28 alone (as a control), in the presence of monensin. FACS® plots show cytokine production by NKT cells from patients with pro-
gressive or nonprogressive myeloma. Data shown are representative of similar experiments on five additional patients.T
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APCs for the expansion of human NKT cells in culture
(27, 32). The use of autologous DCs led to expansion of
NKT cells in all four cohorts (Fig. 4, A and B). Impor-
tantly, NKT cells expanded in cultures with autologous
DCs in all cohorts were functional and secreted both IFN- 
and IL-4 in response to stimulation with PMA and iono-
mycin (unpublished data), as previously shown with
healthy donors (27). These expanded V 24  NKT cells
also secreted both IFN-  and IL-4, in response to  -Gal-
Cer loaded DCs (Fig. 4 C). Thus, although fresh NKT cells
from patients with progressive myeloma did not produce
IFN-  in response to ligand bearing APC, NKT cells ex-
panded from these patients using  -GalCer–loaded DCs,
secreted both IFN-  and IL-4 in response to the ligand.
Expression of CD1d by Primary Myeloma Cells and Cell
Lines. Expression of CD1d by myeloma tumor cells was
tested by flow cytometry. Several myeloma cell lines tested
(arp, ark, RPMI 8226, U266) lacked detectable CD1d ex-
pression. Low but detectable CD1d expression was noted
in one of the cell lines (cag cells; Fig. 5). However in dis-
tinct contrast to cell lines, all fresh tumor cells from my-
eloma patients (n   5) expressed much higher levels of
CD1d (Fig. 5).
Cytotoxicity of Expanded NKT Cells Against Primary Hu-
man Myeloma and Cell Lines. To test the cytolytic capaci-
ties of NKT cells expanded in culture from patients with
monoclonal gammopathies, the expanded cultures were
separated into V 24  and negative fractions using mag-
netic beads, and then tested for killing of myeloma cell lines
and primary myeloma cells. NKT cells expanded from pa-
tients with MGUS or nonprogressive myeloma could kill
CD1d expressing but not CD1d negative myeloma cell
lines in a ligand ( -GalCer)–dependent manner (Fig. 6 A).
Then we tested if NKT cells generated from patients
with  nonprogressive myeloma could kill purified auto-
logous tumor cells. Indeed, V 24  NKT cells (not the
V 24  fraction) killed purified autologous myeloma cells
(CD138 ve) but not nonmyeloma cells (CD138-ve) from
the same tumor bed (Fig. 6 B). Importantly, killing of pri-
mary myeloma cells by activated purified NKT cells did
not require the addition of exogenous  -GalCer to the tar-
gets in the cytolytic assay as was the case with cell lines, al-
though an increase in killing was noted with the addition
of exogenous  -GalCer (Fig. 6 B). Killing of tumor cells
Figure 4. Functional NKT cells can be expanded from patients with
monoclonal gammopathies using  -GalCer pulsed mature DCs. (A) Ex-
pansion of V 24 V 11  NKT cells in culture using autologous  -GalCer
pulsed mature DCs from healthy donors (HD; n   5), or patients with
MGUS (n   4), NPM (n   3), or PM (n   5). Data shown are % NKT
cells in PBMCs determined by flow cytometry before and after 2–3 wk of
expansion. (B) Representative FACS plots showing detection of NKT
cells (V 24  V 11 ) in fresh PBMCs (pre) of patients with MGUS, non-
progressive or progressive myeloma, or after PBMC expansion (post) us-
ing  -GalCer pulsed mature DCs. Percentages refer to percent NKT cells
in total recovered PBMCs. (C) Cytokine production by expanded NKT
cells in response to ligand-bearing APCs. T cells expanded using autolo-
gous  -GalCer pulsed autologous mature DCs as in panel A, were sepa-
rated into NKT (V 24 ) and non-NKT (V 24-ve) fractions using
magnetic beads. Individual fractions were then tested for reactivity to au-
tologous  -GalCer pulsed mature DCs (DC: responder ratio of 1:10), us-
ing a 16 h Elispot assay for IFN-  or IL-4 producing cells. Data shown
are representative of two patients each with PM or NPM.
Figure 5. Expression of CD1d on myeloma cells. CD1d expression on
myeloma cell lines (arp and cag) as well as purified myeloma cells, as assessed
by flow cytometry. Filled histogram reflects isotype control. Data on pri-
mary myeloma cells are representative of five different patients.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
1673 Dhodapkar et al.
was inhibited by preincubation of targets with anti-human
CD1d antibody (unpublished data).
In one of the patients with progressive myeloma, ade-
quate numbers of expanded V 24  NKT and autologous
tumor cells were available to test killing of fresh autologous
tumor from a clinically progressive patient. In this patient,
V 24 , but not the negative fraction could mediate killing
of autologous tumor cells, to a similar extent to the killing
by bulk T cells generated using tumor cell–loaded DCs
(Fig. 6 C). Killing of primary tumor cells by the V 24 
fraction again did not require exogenous  -GalCer, and
nontumor cells from the same tumor bed were not killed
(Fig. 6 C). Killer T cells generated using tumor loaded DCs
are distinct from CD1d restricted NKT cells and mediate
lytic activity in a MHC class I–restricted fashion, as shown
previously (11). These initial studies suggest that the NKT
cells in patients with progressive myeloma are dysfunc-
tional, lacking rapid effector function to ligand specific
stimulation when studied directly from patients, but capa-
ble of rescue by antigen presenting DCs to expand and to
lyse autologous tumor cells.
Discussion
Pioneering studies with spontaneous as well as carcino-
gen induced tumors have suggested a role for T lympho-
cytes, IFN- , NK, and NKT cells in immune-surveillance
and “immune-editing” of cancers in mice (8–10, 33, 34).
However, the clinical picture of stable versus progressive
clonal expansions of transformed cells (as with MGUS/my-
eloma) has been difficult to model in mice, although stable
clonal expansions of transformed cells are now increasingly
apparent in healthy humans (2). In this paper we have
shown that clinical progression in patients with monoclonal
gammopathies is associated with the loss of ligand-depen-
dent IFN-  production by invariant NKT cells. In con-
trast, there was no detectable difference in the antitumor
killer T cell function between patients with progressive or
nonprogressive tumors. The observed NKT cell dysfunc-
tion could however be restored, with the induction of
strong lytic activity against autologous tumor and ligand-
dependent IFN-  secretion in vitro. These data suggest
that NKT effector function represents an important host
factor maintaining control of tumor growth in vivo in pa-
tients with clinically stable gammopathies. IFN-  produc-
tion by these innate lymphocytes may also contribute to
growth control of myeloma by nonimmune mechanisms,
for example by mediating angiostasis (35), controlling tu-
mor growth via decreased IL-6 or STAT-3–mediated tran-
scription (36, 37), and inhibiting osteoclastogenesis (38), all
features of progressive myeloma.
The loss of ligand and NKT dependent IFN-  produc-
tion in progressive myeloma is not simply due to the loss of
invariant NKT cells, as they were detectable by flow cyto-
metric assay with lower sensitivity than the ELISPOT as-
say. The presence of these cells in patients with progressive
myeloma is also supported by the observation that they can
Figure 6. Cytolytic function of NKT cells from patients with gammo-
pathies. (A) Lysis of CD1d positive (cag) or negative (arp) myeloma cell
lines (the lines were tested with or without in vitro pulsing with  -GalCer
[ GC]), by V 24 positive or negative fractions of cultures after in vitro
expansion with  -GalCer pulsed DCs. Additional positive control targets
were U937 histiocytic lymphoma (NKT sensitive) and K562 erythroleu-
kemia cells (NK sensitive). (B) Killing of autologous primary tumor cells
(CD138 positive) versus nontumor cells (CD138 negative) in the tumor
bed, by V 24 positive or negative fraction of cells expanded using  -Gal-
Cer (GC) pulsed DCs (versus unpulsed DCs) from a patient with nonpro-
gressive myeloma. The tumor cells were tested without or with supple-
mentation with  -GalCer (GC) during the lytic assay. Additional control
targets were U937 histiocytic lymphoma and K562 erythroleukemia cells.
Data are representative of similar experiments on two patients. (C) Killing
of autologous primary tumor cells (CD138 ve) versus nontumor cells
(CD138-ve) from the tumor bed of a patient with progressive myeloma.
Killing was measured with bulk T cells expanded using DC only (DC( ))
and DCs loaded with autologous tumor (DC-tum), and for the latter,
V 24 positive or negative fractions from cultures expanded using  -Gal-
Cer pulsed DCs (DC(Gal-Cer)).T
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be readily expanded using  -GalCer pulsed mature DCs.
Another possibility, that we favor, is that the observed loss
of rapid effector function in fresh NKT cells in these pa-
tients reflects the induction of NKT cell dysfunction in as-
sociation with tumor progression. Recent studies in mice
suggest that the presentation of  -GalCer by non-DCs in
vivo may lead to the induction of NKT cell dysfunction
(39). Therefore the presentation of tumor derived glycolip-
ids by tumors themselves, or by other APCs in the tumor
bed (as opposed to DCs), could lead to NKT cell dysfunc-
tion with tumor progression in vivo. Glycolipids shed from
these tumor cells in vivo may also inhibit NKT cell func-
tion (40). In other words, a critical step in the transition to
progressive tumors may be an acquired capacity of the tu-
mor cells to disable the NKT arm of host resistance. Re-
cent studies have suggested functionally distinct subsets
among NKT cells (28, 41). However this is unlikely to ac-
count for our findings, as both subsets identified in these
studies predominantly make IFN- . Further studies are
needed to characterize both the molecular nature of the
glycolipid ligands expressed by these tumor cells in vivo,
and the functional aspects of tumor specific NKT cells, par-
ticularly for potential tumor promoting properties in re-
sponse to tumor derived glycolipids (21).
Although IFN-  production by freshly isolated NKT
cells was deficient in progressive myeloma, these cells could
be expanded after in vitro stimulation with  -GalCer
pulsed DCs. Also the expanded NKT cells were functional
and able to secrete IFN- . However, this expansion was
reduced compared with NKT cells from MGUS or healthy
donors. Diminished expansion of IFN-  producing NKT
cells has also been noted in some patients with advanced
cancer, although DCs were not used in these studies and
cytokine production was only tested after prior in vitro cul-
ture (24, 25).
To our knowledge, this is the first report to correlate
NKT cell function against fresh autologous tumor with
clinical outcome in humans. NKT cells may mediate im-
mune control of tumors both via direct cytotoxicity, as
well as indirectly via release of cytokines and enhancement
of NK or T cell function (18, 22, 42, 43). Although the ex-
isting data for the lysis of tumor cells by human NKT cells
is largely limited to tumor cell lines, our data extend it to
fresh uncultured autologous tumor cells (44), including to
autologous myeloma. Importantly, autologous nontumor
cells in the tumor bed were not killed, which may help al-
lay some of the concerns about potential toxicity if one
would attempt to enhance NKT function therapeutically
with DCs in myeloma. The marked difference in CD1d
expression between cell lines and primary tumors in our
disease model also urges the need to test CD1d expression
in other primary human tumors and explore primary un-
cultured tumor instead of tumor cell lines as targets in im-
mune assays testing antitumor NKT function.
Taken together, our data support the hypothesis that
NKT effector function may play a role in the control of
malignant growth of transformed plasma cells in gammopa-
thies. This would extend the putative role of NKT cells
from immune surveillance (34) to immune control of ma-
lignant behavior of cancer cells in vivo. This is also distinct
from the “immune editing” of tumors described in mice
(8), as progressive tumors remain quite sensitive to NKT
cells activated ex vivo. These data provide impetus for clin-
ical studies to boost or restore NKT cell function in my-
eloma. Measurement of NKT cell function may be a useful
predictor of clinical outcome in these patients.
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